0.10Open0.20Pre Close12 Volume57 Open Interest2.00Strike Price80.00Turnover120.86%IV24.81%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type-0.1435Delta0.3158Gamma43.00Leverage Ratio-0.0042Theta-0.0002Rho-6.17Eff Leverage0.0013Vega
Corvus Pharmaceuticals Stock Discussion
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024
Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024
Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefin...
NEWS
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
NEWS
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
No comment yet